STOCK TITAN

ZEO ScientifiX (OTCQB: ZEOX) supports Peru pediatric burn reconstruction mission

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. filed a report describing a humanitarian initiative supported by the company. Medical Advisory Board member Dr. Constantino Mendieta joined a 10-day pediatric burn reconstruction mission in Cusco, Peru, where he used products that had been donated to him by ZEO ScientifiX.

During the mission, approximately 80 children were evaluated and nearly 40 reconstructive surgeries were performed over six days at the Regional Hospital of Cusco. ZEO frames this product donation as part of a broader commitment to physician-led care, regenerative medicine education, and expanding access to advanced therapeutic options for patients in need.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Mission duration 10 days Length of humanitarian medical mission in Cusco, Peru
Children evaluated approximately 80 children Pediatric burn survivors evaluated during the mission
Reconstructive surgeries nearly 40 surgeries Reconstructive procedures performed over six days
Child patients treated approximately 38 child patients Patients receiving specialized reconstructive care for severe burns
regenerative biologics medical
"a biologics research and products company dedicated to advancing the science and development of regenerative biologics products"
clinical-stage biopharmaceutical company financial
"ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company"
A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.
Medical Advisory Board other
"ZEO’s Medical Advisory Board member Constantino Mendieta, MD, recently participated in a humanitarian medical mission"
forward-looking statements regulatory
"Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
regenerative medicine education medical
"commitment to supporting physician-led care, regenerative medicine education, and initiatives that expand access"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001557376 0001557376 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 16, 2026

 

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-55008   47-4180540
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

3321 College Avenue, Suite 246
Davie, Florida

  33314
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 963-7881

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

 

Item 8.01 Other Events.

 

On June 16, 2026, ZEO issued a press release announcing that ZEO’s Medical Advisory Board member Constantino Mendieta, MD, recently participated in a humanitarian medical mission in Cusco, Peru to provide specialized reconstructive care to treat approximately 38 child patients recovering from severe burn injuries which included the use by Dr. Mendieta of products that had been donated to him by ZEO.

 

A copy of the press release is included as Exhibit 99.1 to this Report.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated June 16, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 16, 2026 ZEO SCIENTIFIX, INC.
     
  By: /s/ Ian T. Bothwell
   

Ian T. Bothwell

Chief Executive Officer and Chief Financial Officer

 

2

 

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru

 

ZEO Medical Advisory Board Member Dr. Constantino Mendieta joins humanitarian effort providing reconstructive

care to children recovering from severe burn injuries in Cusco, Peru

 

DAVIE, FLORIDA — June 16, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”), a biologics research and products company dedicated to advancing the science and development of regenerative biologics products for therapeutic use and a leader in educating physicians on the science of regenerative medicine, announced that ZEO’s Medical Advisory Board member Constantino Mendieta, MD, recently participated in a humanitarian medical mission in Cusco, Peru to provide specialized reconstructive care to treat approximately 38 child patients recovering from severe burn injuries which included the use by Dr. Mendieta of products that had been donated to him by ZEO ScientifiX.

 

The 10-day mission brought together reconstructive surgeons, healthcare professionals, therapists, psychologists, volunteers, and nonprofit organizations to provide care to pediatric burn survivors and their families. During the mission, approximately 80 children were evaluated, with nearly 40 reconstructive surgeries performed over six days at the Regional Hospital of Cusco.

 

“ZEO ScientifiX was honored to support this mission by contributing products that helped make this level of care possible for children and families who may not otherwise have access to specialized reconstructive treatment,” said Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX. “This mission reflects the heart of regenerative medicine — using science, innovation, and physician expertise to improve lives in a meaningful way.”

 

ZEO ScientifiX’s product donation represents part of the Company’s broader commitment to supporting physician-led care, regenerative medicine education, and initiatives that expand access to advanced therapeutic options for patients in need.

 

As part of the mission, Dr. Mendieta worked alongside local and international medical professionals to evaluate patients, develop surgical plans, and perform reconstructive procedures aimed at restoring function, mobility, confidence, and quality of life.

 

“Something that has deeply impacted me during this experience is that many of these children do not see themselves as victims,” said Dr. Mendieta. “They continue to play, laugh, dream, and live with a joy that transcends any visible scar. Their spirits remain unbroken.”

 

The mission also included support from organizations including Aniquem and Fundación Aromas, along with psychologists, therapists, volunteers, healthcare professionals, and supporters whose combined efforts helped children and families move from fear and pain toward healing and renewed confidence.

 

Known for his innovations in reconstructive surgery, Dr. Mendieta serves on the ZEO ScientifiX Medical Advisory Board, where he contributes to physician education and scientific initiatives focused on advancing patient care.

 

Physicians interested in learning more about ZEO ScientifiX’s educational programs and physician partnership opportunities may contact the Company directly.

 

 

 

 

About ZEO ScientifiX (OTCQB: ZEOX)

 

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University’s Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. ZEO ScientifiX supplies clinicians seeking to drive clinical excellence and sustainable practice growth through its cutting-edge biologics and regenerative therapies. For more information, visit https://zeoscientifix.com.

 

Forward-Looking Statements

 

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

 

Media Contact

 

ZEO ScientifiX, Inc.
Karlista Maroney
Director of Growth Strategy
ir@zeoscientifix.com

 

 

FAQ

What did ZEOX disclose in its latest 8-K filing?

ZEO ScientifiX disclosed that a Medical Advisory Board member, Dr. Constantino Mendieta, joined a humanitarian mission in Cusco, Peru, using products donated by the company. The effort focused on reconstructive care for children recovering from severe burn injuries.

How did ZEO ScientifiX (ZEOX) support the pediatric burn mission in Peru?

ZEO ScientifiX supported the mission by donating its products for use by Medical Advisory Board member Dr. Mendieta. These regenerative biologics products were used in reconstructive procedures for child burn survivors at the Regional Hospital of Cusco during the 10-day mission.

How many children were treated during the ZEOX-supported mission in Cusco?

During the mission, approximately 80 children were evaluated and nearly 40 reconstructive surgeries were performed over six days. The work focused on pediatric burn survivors, aiming to improve function, mobility, confidence, and quality of life for the young patients.

What broader commitments did ZEO ScientifiX highlight in this 8-K?

ZEO ScientifiX highlighted that this product donation is part of a broader commitment to supporting physician-led care, regenerative medicine education, and initiatives that expand access to advanced therapeutic options for patients who might otherwise lack specialized reconstructive treatment.

Who is Dr. Constantino Mendieta in relation to ZEOX?

Dr. Constantino Mendieta is a member of ZEO ScientifiX’s Medical Advisory Board and is known for innovations in reconstructive surgery. He contributes to physician education and scientific initiatives for the company and participated in the pediatric burn reconstruction mission in Cusco, Peru.

What does ZEO ScientifiX (OTCQB: ZEOX) focus on as a business?

ZEO ScientifiX is a clinical-stage biopharmaceutical company focused on research, development, and manufacturing of regenerative biologics. Operating from Nova Southeastern University’s Center of Collaborative Research, it supplies clinicians with biologics and regenerative therapies designed to support clinical excellence and practice growth.

Filing Exhibits & Attachments

4 documents